LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 250

Search options

  1. Book ; Online ; E-Book: Calcitonin gene-related peptide (CGRP) mechanisms

    Brain, Susan D. / Geppetti, Pierangelo

    focus on migraine

    (Handbook of experimental pharmacology ; 255)

    2019  

    Author's details Susan D. Brain, Pierangelo Geppetti editors
    Series title Handbook of experimental pharmacology ; 255
    Collection
    Keywords Electronic books
    Language English
    Size 1 Online-Ressource (vii, 192 Seiten), Illustrationen
    Publisher Springer
    Publishing place Cham
    Publishing country Switzerland
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    HBZ-ID HT020208457
    ISBN 978-3-030-21454-8 ; 9783030214531 ; 3-030-21454-0 ; 3030214532
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Full text online

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Book ; Conference proceedings: Peptidergic G-protein coupled receptors

    Geppetti, Pierangelo

    from basic research to clinical applications ; [proceedings of the NATO Advanced Study Institute on Peptidergic G Protein-Coupled Receptors: From Basic Research to Clinical Applications, Erice, Sicily, Italy, 14 - 24 May 1998]

    (NATO ASI series : Series A, Life sciences ; 307)

    1999  

    Title variant G protein-coupled
    Institution NATO
    Event/congress Advanced Study Institute on Peptidergic G Protein Coupled Receptors: From Basic Research to Clinical Applications (1998, Erice)
    Author's details ed. by Pierangelo Geppetti
    Series title NATO ASI series : Series A, Life sciences ; 307
    NATO ASI series
    NATO ASI series ; Series A, Life sciences
    Collection NATO ASI series
    NATO ASI series ; Series A, Life sciences
    Language English
    Size VIII, 225 S. : Ill., graph. Darst.
    Publisher IOS Press u.a.
    Publishing place Amsterdam u.a.
    Publishing country Netherlands
    Document type Book ; Conference proceedings
    HBZ-ID HT011262821
    ISBN 90-5199-441-9 ; 4-274-90279-X ; 978-90-5199-441-4 ; 978-4-274-90279-6
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2000 A 1541 order for loan Magazin

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Book: Neurogenic inflammation

    Geppetti, Pierangelo

    1996  

    Author's details ed. by Pierangelo Geppetti
    Keywords Nervous System / physiology ; Inflammation / physiopathology ; Nervensystem ; Entzündung ; Efferente Nervenfaser ; Neuropeptide
    Subject Inflammatio ; Entzündungsreaktion ; Neuromodulator ; Systema nervosum ; NS
    Language English
    Size 324 S. : Ill., graph. Darst.
    Publisher CRC Press
    Publishing place Boca Raton u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT007354742
    ISBN 0-8493-7646-7 ; 978-0-8493-7646-7
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    1996 A 6111 order for loan Magazin

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Emerging Pharmacological Treatments for Migraine in the Pediatric Population.

    Iannone, Luigi Francesco / De Cesaris, Francesco / Geppetti, Pierangelo

    Life (Basel, Switzerland)

    2022  Volume 12, Issue 4

    Abstract: Headaches in children and adolescents have high incidence and prevalence rates, with consequent elevated disability costs to individuals and the community. Pediatric migraine is a disorder with substantial clinical differences compared to the adult form. ...

    Abstract Headaches in children and adolescents have high incidence and prevalence rates, with consequent elevated disability costs to individuals and the community. Pediatric migraine is a disorder with substantial clinical differences compared to the adult form. Few clinical trials have been performed specifically on primary headache in pediatric populations using acute and preventative treatments, often with conflicting findings. The limited high-quality data on the effectiveness of treatments are also due to the high placebo effect, in terms of reductions in both the frequency and intensity of migraine attacks in the pediatric population. The recent introduction of calcitonin gene-related peptide (CGRP) pathway inhibitors and ditans is changing the treatment of migraine, but the majority of the data are still limited to adulthood. Thus, few drugs have indications for migraine treatment in the pediatric age group, and limited evidence gives guidance as to the choice of pharmacotherapy. Herein, we review the current evidence of pharmacological treatments and ongoing clinical trials on acute and preventative treatments in the pediatric population with migraine.
    Language English
    Publishing date 2022-04-05
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2662250-6
    ISSN 2075-1729
    ISSN 2075-1729
    DOI 10.3390/life12040536
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Emerging Pharmacological Treatments for Migraine in the Pediatric Population

    Luigi Francesco Iannone / Francesco De Cesaris / Pierangelo Geppetti

    Life, Vol 12, Iss 536, p

    2022  Volume 536

    Abstract: Headaches in children and adolescents have high incidence and prevalence rates, with consequent elevated disability costs to individuals and the community. Pediatric migraine is a disorder with substantial clinical differences compared to the adult form. ...

    Abstract Headaches in children and adolescents have high incidence and prevalence rates, with consequent elevated disability costs to individuals and the community. Pediatric migraine is a disorder with substantial clinical differences compared to the adult form. Few clinical trials have been performed specifically on primary headache in pediatric populations using acute and preventative treatments, often with conflicting findings. The limited high-quality data on the effectiveness of treatments are also due to the high placebo effect, in terms of reductions in both the frequency and intensity of migraine attacks in the pediatric population. The recent introduction of calcitonin gene-related peptide (CGRP) pathway inhibitors and ditans is changing the treatment of migraine, but the majority of the data are still limited to adulthood. Thus, few drugs have indications for migraine treatment in the pediatric age group, and limited evidence gives guidance as to the choice of pharmacotherapy. Herein, we review the current evidence of pharmacological treatments and ongoing clinical trials on acute and preventative treatments in the pediatric population with migraine.
    Keywords CGRP ; monoclonal antibodies ; gepants ; childhood ; adolescents ; migraine ; Science ; Q
    Subject code 610
    Language English
    Publishing date 2022-04-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: The first interim analysis of Italian patients enrolled in the real-world, Pan-European, prospective, observational, phase 4 PEARL study of fremanezumab effectiveness.

    Tassorelli, Cristina / Barbanti, Piero / Finocchi, Cinzia / Geppetti, Pierangelo / Kokturk, Pinar / Russo, Antonio / Sacco, Simona / Cepparulo, Mario

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

    2024  Volume 45, Issue 5, Page(s) 2353–2363

    Abstract: Introduction: In 2020, the Italian Medicines Agency (AIFA) approved the reimbursement of calcitonin gene-related peptide (CGRP) pathway monoclonal antibodies (mAbs), including fremanezumab, in patients with a Migraine Disability Assessment Scale (MIDAS) ...

    Abstract Introduction: In 2020, the Italian Medicines Agency (AIFA) approved the reimbursement of calcitonin gene-related peptide (CGRP) pathway monoclonal antibodies (mAbs), including fremanezumab, in patients with a Migraine Disability Assessment Scale (MIDAS) score ≥ 11, with prescription renewals for up to 12 months in patients with ≥ 50% reduction in MIDAS score at Months 3 and 6. In this sub-analysis of the Pan-European Real Life (PEARL) study, we provide real-world data on fremanezumab use in Italian routine clinical practice (EUPAS35111).
    Methods: This first interim analysis for Italy was conducted when 300 enrolled adult patients with episodic or chronic migraine (EM, CM) completed 6 months of treatment with fremanezumab. The primary endpoint is the proportion of patients achieving ≥ 50% reduction in monthly migraine days (MMD) across the 6 months post-fremanezumab initiation. Secondary endpoints include: proportion of patients achieving ≥ 50% reduction in MIDAS score at Months 3 and 6, and mean change from baseline across Months 1-6 in MMD and headache-related disability. Safety was assessed through adverse events (AEs) reported.
    Results: Of 354 patients enrolled at Italian centers, 318 (EM, 35.5%, CM, 64.5%) were included in the effectiveness analysis. Of patients with available data, 109 (61.2%) achieved the primary endpoint. 61.0% and 65.1% achieved ≥ 50% reduction in MMDs at Months 3 and 6, respectively; 79.9% and 81.0% experienced ≥ 50% reduction in MIDAS at the same timepoints.
    Conclusion: Fremanezumab was effective and well-tolerated over the first 6 months of treatment, with approximately 80% of patients meeting Italian criteria for treatment continuation at Months 3 and 6.
    MeSH term(s) Adult ; Humans ; Prospective Studies ; Double-Blind Method ; Antibodies, Monoclonal/adverse effects ; Migraine Disorders/drug therapy ; Treatment Outcome
    Chemical Substances fremanezumab ; Antibodies, Monoclonal
    Language English
    Publishing date 2024-03-01
    Publishing country Italy
    Document type Observational Study ; Clinical Trial, Phase IV ; Journal Article
    ZDB-ID 2016546-8
    ISSN 1590-3478 ; 1590-1874
    ISSN (online) 1590-3478
    ISSN 1590-1874
    DOI 10.1007/s10072-024-07357-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1877: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Ion Channel Pharmacology for Pain Modulation.

    De Logu, Francesco / Geppetti, Pierangelo

    Handbook of experimental pharmacology

    2019  Volume 260, Page(s) 161–186

    Abstract: A large series of different ion channels have been identified and investigated as potential targets for new medicines for the treatment of a variety of human diseases, including pain. Among these channels, the voltage gated calcium channels (VGCC) are ... ...

    Abstract A large series of different ion channels have been identified and investigated as potential targets for new medicines for the treatment of a variety of human diseases, including pain. Among these channels, the voltage gated calcium channels (VGCC) are inhibited by drugs for the treatment of migraine, neuropathic pain or intractable pain. Transient receptor potential (TRP) channels are emerging as important pain transducers as they sense low pH media or oxidative stress and other mediators and are abundantly found at sites of inflammation or tissue injury. Low pH may also activate acid sensing ion channels (ASIC) and mechanical forces stimulate the PIEZO channels. While potent agonists of TRP channels due to their desensitizing action on pain transmission are used as topical applications, the potential of TRP antagonists as pain therapeutics remains an exciting field of investigation. The study of ASIC or PIEZO channels in pain signaling is in an early stage, whereas antagonism of the purinergic P2X
    MeSH term(s) Acid Sensing Ion Channel Blockers/therapeutic use ; Acid Sensing Ion Channels ; Calcium Channel Blockers/therapeutic use ; Calcium Channels ; Humans ; Inflammation ; Neuralgia/drug therapy ; Pain Management ; Transient Receptor Potential Channels/antagonists & inhibitors
    Chemical Substances Acid Sensing Ion Channel Blockers ; Acid Sensing Ion Channels ; Calcium Channel Blockers ; Calcium Channels ; Transient Receptor Potential Channels
    Language English
    Publishing date 2019-12-09
    Publishing country Germany
    Document type Journal Article ; Review
    ISSN 0171-2004
    ISSN 0171-2004
    DOI 10.1007/164_2019_336
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Sign. bis Bd. 125 (1997): 1982 A 2146: Show issues
     danach: Sign. bei den Einzelbänden: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: COVID-19 pneumonia during long-term migraine prophylaxis with fremanezumab: a case report.

    Iannone, Luigi Francesco / Geppetti, Pierangelo / Chiarugi, Alberto / De Cesaris, Francesco

    Internal and emergency medicine

    2021  Volume 16, Issue 8, Page(s) 2309–2311

    MeSH term(s) Adult ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; COVID-19/complications ; COVID-19/diagnosis ; COVID-19/drug therapy ; Dose-Response Relationship, Drug ; Female ; Humans ; Migraine Disorders/complications ; Migraine Disorders/drug therapy ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; fremanezumab
    Language English
    Publishing date 2021-06-12
    Publishing country Italy
    Document type Case Reports ; Letter
    ZDB-ID 2454173-4
    ISSN 1970-9366 ; 1828-0447
    ISSN (online) 1970-9366
    ISSN 1828-0447
    DOI 10.1007/s11739-021-02787-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6673: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Neuronal and non-neuronal TRPA1 as therapeutic targets for pain and headache relief.

    Iannone, Luigi F / Nassini, Romina / Patacchini, Riccardo / Geppetti, Pierangelo / De Logu, Francesco

    Temperature (Austin, Tex.)

    2022  Volume 10, Issue 1, Page(s) 50–66

    Abstract: The transient receptor potential ankyrin 1 (TRPA1), a member of the TRP superfamily of channels, has a major role in different types of pain. TRPA1 is primarily localized to a subpopulation of primary sensory neurons of the trigeminal, vagal, and dorsal ... ...

    Abstract The transient receptor potential ankyrin 1 (TRPA1), a member of the TRP superfamily of channels, has a major role in different types of pain. TRPA1 is primarily localized to a subpopulation of primary sensory neurons of the trigeminal, vagal, and dorsal root ganglia. This subset of nociceptors produces and releases the neuropeptide substance P (SP) and calcitonin gene-related peptide (CGRP), which mediate neurogenic inflammation. TRPA1 is characterized by unique sensitivity for an unprecedented number of reactive byproducts of oxidative, nitrative, and carbonylic stress and to be activated by several chemically heterogenous, exogenous, and endogenous compounds. Recent preclinical evidence has revealed that expression of TRPA1 is not limited to neurons, but its functional role has been reported in central and peripheral glial cells. In particular, Schwann cell TRPA1 was recently implicated in sustaining mechanical and thermal (cold) hypersensitivity in mouse models of macrophage-dependent and macrophage-independent inflammatory, neuropathic, cancer, and migraine pain. Some analgesics and herbal medicines/natural products widely used for the acute treatment of pain and headache have shown some inhibitory action at TRPA1. A series of high affinity and selective TRPA1 antagonists have been developed and are currently being tested in phase I and phase II clinical trials for different diseases with a prominent pain component.
    Language English
    Publishing date 2022-05-29
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2332-8940
    ISSN 2332-8940
    DOI 10.1080/23328940.2022.2075218
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  10. Article ; Online: Antiseizure Medications for the Prophylaxis of Migraine during the Anti- CGRP Drugs Era.

    Rollo, Eleonora / Romozzi, Marina / Vollono, Catello / Calabresi, Paolo / Geppetti, Pierangelo / Iannone, Luigi F

    Current neuropharmacology

    2022  Volume 21, Issue 8, Page(s) 1767–1785

    Abstract: Migraine and epilepsy are fundamentally distinct disorders that can frequently coexist in the same patient. These two conditions significantly differ in diagnosis and therapy but share some widely- used preventive treatments. Antiseizure medications ( ... ...

    Abstract Migraine and epilepsy are fundamentally distinct disorders that can frequently coexist in the same patient. These two conditions significantly differ in diagnosis and therapy but share some widely- used preventive treatments. Antiseizure medications (ASMs) are the mainstay of therapy for epilepsy, and about thirty different ASMs are available to date. ASMs are widely prescribed for other neurological and non-neurological conditions, including migraine. However, only topiramate and valproic acid/valproate currently have an indication for migraine prophylaxis supported by high-quality evidence. Although without specifically approved indications and with a low level of evidence or recommendation, several other ASMs are used for migraine prophylaxis. Understanding ASM antimigraine mechanisms, including their ability to affect the pro-migraine calcitonin gene-related peptide (CGRP) signaling pathway and other pathways, may be instrumental in identifying the specific targets of their antimigraine efficacy and may increase awareness of the neurobiological differences between epilepsy and migraine. Several new ASMs are under clinical testing or have been approved for epilepsy in recent years, providing novel potential drugs for migraine prevention to enrich the treatment armamentarium and drugs that inhibit the CGRP pathway.
    MeSH term(s) Humans ; Animals ; Migraine Disorders/drug therapy ; Migraine Disorders/prevention & control ; Calcitonin Gene-Related Peptide Receptor Antagonists/therapeutic use ; Seizures/drug therapy ; Drug Approval ; Anticonvulsants/therapeutic use
    Chemical Substances Calcitonin Gene-Related Peptide Receptor Antagonists ; Anticonvulsants
    Language English
    Publishing date 2022-12-28
    Publishing country United Arab Emirates
    Document type Journal Article ; Review
    ZDB-ID 2192352-8
    ISSN 1875-6190 ; 1570-159X
    ISSN (online) 1875-6190
    ISSN 1570-159X
    DOI 10.2174/1570159X21666221228095256
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6150: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top